Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pembrolizumab|PROCEDURE: Core Biopsy/Cryoablation|PROCEDURE: Breast Surgery|DRUG: Ipilimumab|DRUG: Nivolumab
Sponsor: University of Texas Southwestern Medical Center
Collaborators: Susan G. Komen Breast Cancer Foundation|Bristol-Myers Squibb|Boston Scientific Corporation|American Society of Clinical Oncology